Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $36.33 Average Target Price from Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have received a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $36.33.

A number of research analysts have weighed in on the stock. BTIG Research boosted their price objective on shares of Viridian Therapeutics from $56.00 to $61.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. Needham & Company LLC restated a “buy” rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Wednesday, November 13th. The Goldman Sachs Group upped their price target on shares of Viridian Therapeutics from $25.00 to $31.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Oppenheimer restated an “outperform” rating and issued a $28.00 price target (down from $31.00) on shares of Viridian Therapeutics in a report on Monday, August 12th. Finally, Royal Bank of Canada restated an “outperform” rating and issued a $44.00 price target on shares of Viridian Therapeutics in a report on Thursday, September 19th.

Viridian Therapeutics Price Performance

VRDN stock opened at $20.24 on Friday. Viridian Therapeutics has a one year low of $11.40 and a one year high of $27.20. The company’s fifty day moving average price is $22.79 and its 200-day moving average price is $17.09. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $1.60 billion, a PE ratio of -4.70 and a beta of 1.10.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). The business had revenue of $0.09 million for the quarter, compared to analysts’ expectations of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. On average, equities analysts anticipate that Viridian Therapeutics will post -4.01 EPS for the current fiscal year.

Insider Transactions at Viridian Therapeutics

In related news, COO Thomas W. Beetham purchased 5,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were purchased at an average price of $23.41 per share, with a total value of $117,050.00. Following the purchase, the chief operating officer now owns 6,000 shares of the company’s stock, valued at $140,460. The trade was a 500.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Stephen F. Mahoney purchased 21,400 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The stock was bought at an average cost of $23.33 per share, for a total transaction of $499,262.00. Following the purchase, the chief executive officer now directly owns 21,400 shares in the company, valued at $499,262. This trade represents a ? increase in their position. The disclosure for this purchase can be found here. Insiders have bought 1,626,400 shares of company stock valued at $30,616,312 in the last 90 days. 0.65% of the stock is currently owned by company insiders.

Institutional Trading of Viridian Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ameritas Investment Partners Inc. raised its holdings in Viridian Therapeutics by 19.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,961 shares of the company’s stock valued at $87,000 after buying an additional 799 shares during the period. Quest Partners LLC grew its position in Viridian Therapeutics by 344.0% in the 2nd quarter. Quest Partners LLC now owns 6,056 shares of the company’s stock valued at $79,000 after acquiring an additional 4,692 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Viridian Therapeutics in the 3rd quarter valued at about $149,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Viridian Therapeutics in the 3rd quarter valued at about $208,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Viridian Therapeutics by 24.6% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,961 shares of the company’s stock valued at $156,000 after acquiring an additional 2,359 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.